Abstract
Periodontal wafers intended to treat the underlying infections in patients with periodontitis have been developed. The wafers consist of poly(lactic-co-glycolic acid) as a primary bioerodible polymeric component, poly(ethylene glycol) as a plasticizer and encapsulation aid, and silver nitrate as the antimicrobial agent. The wafers are capable of sustained in vitro release of bioactive silver for at least 4 weeks. The wafers exhibit silver release that follows erosion kinetics, confirming a bulk erosion/release mechanism. In clinical evaluation, sustained release of silver at bactericidal levels for at least 21 days is observed. Staining of hard and soft tissues due to the released silver is minimal and reversible.
MeSH terms
-
Administration, Buccal
-
Anti-Infective Agents / pharmacokinetics*
-
Anti-Infective Agents / therapeutic use
-
Delayed-Action Preparations
-
Drug Carriers / pharmacokinetics
-
Drug Carriers / therapeutic use
-
Drug Delivery Systems
-
Gingival Crevicular Fluid / metabolism*
-
Glycolates / pharmacokinetics
-
Glycolates / therapeutic use
-
Humans
-
Keratolytic Agents / pharmacokinetics
-
Keratolytic Agents / therapeutic use
-
Lactic Acid / pharmacokinetics
-
Lactic Acid / therapeutic use
-
Periodontitis / drug therapy
-
Periodontitis / metabolism*
-
Polyesters
-
Polyethylene Glycols / pharmacokinetics
-
Polyethylene Glycols / therapeutic use
-
Polymers / pharmacokinetics
-
Polymers / therapeutic use
-
Silver Nitrate / pharmacokinetics*
-
Silver Nitrate / therapeutic use
-
Solvents / pharmacokinetics
-
Solvents / therapeutic use
Substances
-
Anti-Infective Agents
-
Delayed-Action Preparations
-
Drug Carriers
-
Glycolates
-
Keratolytic Agents
-
Polyesters
-
Polymers
-
Solvents
-
glycolic acid
-
Lactic Acid
-
Polyethylene Glycols
-
poly(lactide)
-
Silver Nitrate